Prospective Observational Study of Baseline Tumor Genomic Profiling and Circulating Tumor DNA in Neoadjuvant Chemoimmunotherapy for Stage IB-III Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this observational study is to learn whether tests on tumor tissue and blood can predict how well patients with stage IB-III non-small cell lung cancer respond to chemotherapy combined with immunotherapy given before surgery (neoadjuvant chemoimmunotherapy). The main questions it aims to answer are: 1. Can tissue-based biomarkers, including genomic profiling of the tumor before treatment, identify at the time of diagnosis patients who are unlikely or likely to respond to neoadjuvant chemoimmunotherapy? 2. Can blood-based, non-invasive biomarkers, such as circulating tumor DNA, predict pathologic complete response (no remaining cancer cells in the surgical specimen) before surgery? Participants will receive neoadjuvant chemoimmunotherapy and surgery as part of their usual care. Tumor tissue obtained at diagnosis will be analyzed by genomic profiling, and blood samples will be collected at several time points, including before and during neoadjuvant treatment, before surgery, and during follow-up after surgery. Treatment will not be changed by this study. Researchers will compare these test results with the response observed in the surgical specimen and with long-term outcomes such as cancer recurrence.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak płuca w stadium IB-III
- •Brak specjalnych mutacji EGFR i ALK
- •Dobry stan zdrowia ogólny (ECOG 0-1)
- •Wiek 19 lat i więcej
- •Podpisana zgoda na udział w badaniu
✗ Disqualifies
- •Wiek poniżej 19 lat
- •Historia poważnych infekcji lub inne poważne problemy zdrowotne
- •Niemożliwość wykonania procedur badania z powodu braku zdolności medycznej
- •Ciąża i inne stany uznane za niezgodne z udziałem w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Locations (1)
Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine
Seoul, South Korea
Trial contact
Tae Hee Hong, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.